At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Paclitaxel Albumin-Stabilized Nanoparticle Formulation +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix
In Brief
A Phase 2 clinical trial evaluating Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Laboratory Biomarker Analysis for Cervical Adenocarcinoma and 4 related conditions. Completed, enrolled 37 participants across 26 sites.
Detailed Summary
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartNov 2006
Primary CompletionFeb 2011
TodayJul 2026
First PostedApr 3, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.2 years ago
Interventions
Paclitaxel Albumin-Stabilized Nanoparticle Formulationdrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies